| Applications of fluorine in medicinal chemistry EP Gillis, KJ Eastman, MD Hill, DJ Donnelly, NA Meanwell Journal of medicinal chemistry 58 (21), 8315-8359, 2015 | 2634 | 2015 |
| Synopsis of some recent tactical application of bioisosteres in drug design NA Meanwell Journal of medicinal chemistry 54 (8), 2529-2591, 2011 | 2535 | 2011 |
| Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design NA Meanwell Journal of medicinal chemistry 61 (14), 5822-5880, 2018 | 1413 | 2018 |
| Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect M Gao, RE Nettles, M Belema, LB Snyder, VN Nguyen, RA Fridell, ... Nature 465 (7294), 96-100, 2010 | 1097 | 2010 |
| A survey of the role of noncovalent sulfur interactions in drug design BR Beno, KS Yeung, MD Bartberger, LD Pennington, NA Meanwell Journal of medicinal chemistry 58 (11), 4383-4438, 2015 | 597 | 2015 |
| Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety NA Meanwell Chemical research in toxicology 24 (9), 1420-1456, 2011 | 522 | 2011 |
| The expanding role of prodrugs in contemporary drug design and development J Rautio, NA Meanwell, L Di, MJ Hageman Nature reviews drug discovery 17 (8), 559-587, 2018 | 508 | 2018 |
| A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding PF Lin, W Blair, T Wang, T Spicer, Q Guo, N Zhou, YF Gong, HGH Wang, ... Proceedings of the National Academy of Sciences 100 (19), 11013-11018, 2003 | 477 | 2003 |
| Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels VK Gribkoff, JE Starrett, SI Dworetzky, P Hewawasam, CG Boissard, ... Nature medicine 7 (4), 471-477, 2001 | 341 | 2001 |
| Metabolic and pharmaceutical aspects of fluorinated compounds BM Johnson, YZ Shu, X Zhuo, NA Meanwell Journal of Medicinal Chemistry 63 (12), 6315-6386, 2020 | 321 | 2020 |
| Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That … T Wang, Z Zhang, OB Wallace, M Deshpande, H Fang, Z Yang, ... Journal of medicinal chemistry 46 (20), 4236-4239, 2003 | 280 | 2003 |
| Hepatitis C virus inhibitors C Bachand, M Belema, DH Deon, AC Good, J Goodrich, CA James, ... | 257* | 2008 |
| Identification of hepatitis C virus NS5A inhibitors JA Lemm, D O'Boyle, M Liu, PT Nower, R Colonno, MS Deshpande, ... Journal of virology 84 (1), 482-491, 2010 | 241 | 2010 |
| Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions Q Guo, HT Ho, I Dicker, L Fan, N Zhou, J Friborg, T Wang, BV McAuliffe, ... Journal of virology 77 (19), 10528-10536, 2003 | 218 | 2003 |
| Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) F McPhee, AK Sheaffer, J Friborg, D Hernandez, P Falk, G Zhai, S Levine, ... Antimicrobial agents and chemotherapy 56 (10), 5387-5396, 2012 | 216 | 2012 |
| Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. VK Gribkoff, JT Lum-Ragan, CG Boissard, DJ Post-Munson, NA Meanwell, ... Molecular pharmacology 50 (1), 206-217, 1996 | 206 | 1996 |
| Azetidin-2-one derivatives as inhibitors of thrombin WT Han, AK Trehan, JJK Wright, ME Federici, SM Seiler, NA Meanwell Bioorganic & Medicinal Chemistry 3 (8), 1123-1143, 1995 | 205 | 1995 |
| Synthesis and structure− activity relationships of 3-aryloxindoles: A new class of calcium-dependent, large conductance potassium (Maxi-K) channel openers with neuroprotective … P Hewawasam, M Erway, SL Moon, J Knipe, H Weiner, CG Boissard, ... Journal of medicinal chemistry 45 (7), 1487-1499, 2002 | 193 | 2002 |
| The synthesis and characterization of BMS-204352 (MaxiPost™) and related 3-fluorooxindoles as openers of maxi-K potassium channels P Hewawasam, VK Gribkoff, Y Pendri, SI Dworetzky, NA Meanwell, ... Bioorganic & medicinal chemistry letters 12 (7), 1023-1026, 2002 | 178 | 2002 |
| Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space NA Meanwell Chemical Research in Toxicology 29 (4), 564-616, 2016 | 171 | 2016 |
Mark KrystalViiV Healtcare在 viivhealthcare.com 的电子邮件经过验证
